{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:31:03Z","timestamp":1763573463783,"version":"3.45.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,19]]},"DOI":"10.7759\/cureus.97252","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:24:28Z","timestamp":1763573068000},"source":"Crossref","is-referenced-by-count":0,"title":["Concurrent Use of Anifrolumab and Belimumab in a Patient With Systemic Lupus Erythematosus Presenting With Recurrent Severe Cutaneous Involvement and Lupus Nephritis"],"prefix":"10.7759","author":[{"given":"Maria Dolores","family":"Manj\u00f3n-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J","family":"Borrego-Utiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enoc","family":"Merino-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Gil-Morillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agust\u00edn","family":"Colodro-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.09.009","article-title":"Leveraging heterogeneity in systemic lupus erythematosus for new therapies","volume":"27","author":"Allen ME","year":"2021","unstructured":"Allen ME, Rus V, Szeto GL. Leveraging heterogeneity in systemic lupus erythematosus for new therapies. Trends Mol Med. 2021, 27:152-71. 10.1016\/j.molmed.2020.09.009","journal-title":"Trends Mol Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63966","article-title":"Evaluation of the efficacy and safety of anifrolumab in moderate-to-severe systemic lupus erythematosus","volume":"16","author":"Cingireddy AR","year":"2024","unstructured":"Cingireddy AR, Ramini N, Cingireddy AR. Evaluation of the efficacy and safety of anifrolumab in moderate-to-severe systemic lupus erythematosus. Cureus. 2024, 16:e63966. 10.7759\/cureus.63966","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241273023","article-title":"Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: a case series of 18 patients","volume":"33","author":"Flouda S","year":"2024","unstructured":"Flouda S, Emmanouilidou E, Karamanakos A, et al.. Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: a case series of 18 patients. Lupus. 2024, 33:1248-53. 10.1177\/09612033241273023","journal-title":"Lupus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead568","article-title":"Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry","volume":"63","author":"Miyazaki Y","year":"2024","unstructured":"Miyazaki Y, Funada M, Nakayamada S, et al.. Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry. Rheumatology (Oxford). 2024, 63:2345-54. 10.1093\/rheumatology\/kead568","journal-title":"Rheumatology (Oxford)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital EM","year":"2022","unstructured":"Vital EM, Merrill JT, Morand EF, et al.. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022, 81:951-61. 10.1136\/annrheumdis-2021-221425","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122525","article-title":"Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients","volume":"3","author":"Huang W","year":"2018","unstructured":"Huang W, Quach TD, Dascalu C, et al.. Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients. JCI Insight. 2018, 3:e122525. 10.1172\/jci.insight.122525","journal-title":"JCI Insight"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie R","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, et al.. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020, 383:1117-28. 10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102729","article-title":"Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort","volume":"124","author":"Gatto M","year":"2021","unstructured":"Gatto M, Saccon F, Andreoli L, et al.. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. J Autoimmun. 2021, 124:102729. 10.1016\/j.jaut.2021.102729","journal-title":"J Autoimmun"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.866319","article-title":"A systematic review of the progression of cutaneous lupus to systemic lupus erythematosus","volume":"13","author":"Curtiss P","year":"2022","unstructured":"Curtiss P, Walker AM, Chong BF. A systematic review of the progression of cutaneous lupus to systemic lupus erythematosus. Front Immunol. 2022, 13:866319. 10.3389\/fimmu.2022.866319","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.915828","article-title":"Current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus","volume":"9","author":"Fetter T","year":"2022","unstructured":"Fetter T, Braegelmann C, de Vos L, Wenzel J. Current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus. Front Med (Lausanne). 2022, 9:915828. 10.3389\/fmed.2022.915828","journal-title":"Front Med (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252010905","article-title":"Lymphocytes change their phenotype and function in systemic lupus erythematosus and lupus nephritis","volume":"25","author":"Moysidou E","year":"2024","unstructured":"Moysidou E, Christodoulou M, Lioulios G, et al.. Lymphocytes change their phenotype and function in systemic lupus erythematosus and lupus nephritis. Int J Mol Sci. 2024, 25:10905. 10.3390\/ijms252010905","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders HJ","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020, 6:7. 10.1038\/s41572-019-0141-9","journal-title":"Nat Rev Dis Primers"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2017.1311936","article-title":"Clinical and histologic features of azathioprine-induced hepatotoxicity","volume":"52","author":"Siramolpiwat S","year":"2017","unstructured":"Siramolpiwat S, Sakonlaya D. Clinical and histologic features of azathioprine-induced hepatotoxicity. Scand J Gastroenterol. 2017, 52:876-80. 10.1080\/00365521.2017.1311936","journal-title":"Scand J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter LM","year":"2023","unstructured":"Carter LM, Wigston Z, Laws P, Vital EM. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Br J Dermatol. 2023, 189:210-8. 10.1093\/bjd\/ljad089","journal-title":"Br J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39553","article-title":"Role of anifrolumab in refractory cutaneous manifestations of lupus erythematosus: a case series and literature review","volume":"15","author":"Khan MA","year":"2023","unstructured":"Khan MA, Khan FH, Khan HB, Saadeh C, Davey N. Role of anifrolumab in refractory cutaneous manifestations of lupus erythematosus: a case series and literature review. Cureus. 2023, 15:e39553. 10.7759\/cureus.39553","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001007","article-title":"Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE","volume":"10","author":"Bao A","year":"2023","unstructured":"Bao A, Petri MA, Fava A, Kang J. Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE. Lupus Sci Med. 2023, 10:e001007. 10.1136\/lupus-2023-001007","journal-title":"Lupus Sci Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne D","year":"2022","unstructured":"Jayne D, Rovin B, Mysler EF, et al.. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022, 81:496-506. 10.1136\/annrheumdis-2021-221478","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae023","article-title":"Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab","volume":"64","author":"J\u00e4gerback S","year":"2025","unstructured":"J\u00e4gerback S, Gomez A, Parodis I. Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab. Rheumatology (Oxford). 2025, 64:623-31. 10.1093\/rheumatology\/keae023","journal-title":"Rheumatology (Oxford)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.890522","article-title":"Understanding the concept of pre-clinical autoimmunity: prediction and prevention of systemic lupus erythematosus: identifying risk factors and developing strategies against disease development","volume":"13","author":"Choi MY","year":"2022","unstructured":"Choi MY, Costenbader KH. Understanding the concept of pre-clinical autoimmunity: prediction and prevention of systemic lupus erythematosus: identifying risk factors and developing strategies against disease development. Front Immunol. 2022, 13:890522. 10.3389\/fimmu.2022.890522","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000394","article-title":"Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease","volume":"7","author":"Nikolopoulos DS","year":"2020","unstructured":"Nikolopoulos DS, Kostopoulou M, Pieta A, et al.. Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease. Lupus Sci Med. 2020, 7:e000394. 10.1136\/lupus-2020-000394","journal-title":"Lupus Sci Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.980079","article-title":"Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment","volume":"13","author":"Kirou KA","year":"2022","unstructured":"Kirou KA, Dall Era M, Aranow C, Anders HJ. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol. 2022, 13:980079. 10.3389\/fimmu.2022.980079","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision medicine in systemic lupus erythematosus","volume":"19","author":"Fasano S","year":"2023","unstructured":"Fasano S, Milone A, Nicoletti GF, Isenberg DA, Ciccia F. Precision medicine in systemic lupus erythematosus. Nat Rev Rheumatol. 2023, 19:331-42. 10.1038\/s41584-023-00948-y","journal-title":"Nat Rev Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430820-concurrent-use-of-anifrolumab-and-belimumab-in-a-patient-with-systemic-lupus-erythematosus-presenting-with-recurrent-severe-cutaneous-involvement-and-lupus-nephritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:24:29Z","timestamp":1763573069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430820-concurrent-use-of-anifrolumab-and-belimumab-in-a-patient-with-systemic-lupus-erythematosus-presenting-with-recurrent-severe-cutaneous-involvement-and-lupus-nephritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.97252","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}